News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 541–576
- Matches
- 32579
- Sources here
- 19
- Companies here
- 35
Search results
Stored financial headlines
Active search
32579 matching headlines
Ticker or company: HEMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Elmet (ELMT) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Peter V. Anania Chief Financial Officer - Michael Lee Full Conference Call Transcript Operator: Good morning. Welcome to the Elmet Group Company …
ELMT
main company
Sharemaestro market context
Stored weekly price path
17 weeks +10.7% · Next-week setup negative 33.5%
Cosmos Health signs exclusive Saudi distribution deal for supplements
Cosmos Health Inc. has secured an exclusive distribution agreement with Innova Healthcare for its Sky Premium Life food supplements in Saudi Arabia. The five-year deal, renewable for another five, includes an initial purchase order of 126,000 units and anticipates over 5 million units in …
COSM
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.1% · Next-week setup negative 39.4%
UnitedHealth Group stock holds steady as healthcare sector hits record high
UnitedHealth Group stock is trading below its recent peak despite the S&P 500 healthcare sector reaching a record high, driven by strong investor appetite. The company's diverse operations, including UnitedHealthcare insurance and the Optum services platform, along with its consistent dividend stream, support its …
UNH
main company
Sharemaestro market context
Trend signal active
52 weeks +34.2%
Craig-Hallum Initiates Coverage on Quince Therapeutics (QNCX) with Buy Rating, $68 Price Target
Craig-Hallum has initiated coverage on Quince Therapeutics (QNCX) with a Buy rating and a $68 price target, driven by the potential of its acquired drug candidate LAM-001. Despite having no revenue and a low GF Score™ of 24/100, the firm highlights the company's moderate …
QNCX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -89.6% · Next-week setup negative 43.4%
NOAA Publishes TMC USA's Consolidated Application for an Exploration License and Commercial Recovery Permit for TMC USA-A in the Federal Register
The National Oceanic and Atmospheric Administration (NOAA) has published TMC USA's consolidated application for an exploration license and commercial recovery permit for polymetallic nodules in the Federal Register. This marks a significant milestone for TMC, a subsidiary of The Metals Company, as it initiates …
TMC
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.5% · Next-week setup negative 38.4%
J. M. Smucker (SJM) Refreshes Jif Branding, Is The Stock Fairly Valued?
J. M. Smucker (SJM) has refreshed its Jif peanut butter branding and introduced new product formats, marking the first major update in over 30 years. Despite recent share price gains, the stock trades slightly below analyst targets and internal fair value estimates, which stands …
SJM
main company
Sharemaestro market context
Trend signal active
52 weeks +10.6% · Next-week setup negative 42.1%
J.M. Smucker Names Jeff Varcoe SVP of Science and Technical Excellence
The J.M. Smucker Co. has appointed Jeff Varcoe, PhD, as Senior Vice President of Science and Technical Excellence, expanding his role from quality assurance and food safety. In this new position, Varcoe will lead operational performance across product development, safety, quality, and regulatory compliance …
SJM
main company
Sharemaestro market context
Trend signal active
52 weeks +10.6% · Next-week setup negative 42.1%
Coca-Cola stock hits all-time high at 90.92 USD
Coca-Cola's stock has reached an all-time high of $90.92, reflecting a 28.63% increase over the past year and underscoring robust growth and investor confidence. Despite appearing overvalued by InvestingPro analysis, the company's consistent dividend increases for 55 years highlight its financial strength. Recent strong …
KO
main company
Sharemaestro market context
Trend signal active
52 weeks +28.6%
ProQR a new buy at BoA on RNA-editing platform
[bad day at wall street] franckreporter * Bank of America Securities has initiated coverage of ProQR Therapeutics (PRQR [https://seekingalpha.com/symbol/PRQR]) at buy, saying that the company's Axiomer RNA-editing platform has been validated, supporting its pipeline. * The bank has an $8 price target (~260% return …
PRQR
main company
Sharemaestro market context
Trend signal active
52 weeks -15.0%
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Brendan Strong President and Chief Executive Officer - Richard Paulson Chief Medical Officer - Reshma Rangwala Chief Commercial Officer - Sohanya Cheng …
KPTI
main company
Sharemaestro market context
Price below Trend Line
52 weeks -67.9% · Next-week setup negative 42.9%
Aardvark Therapeutics Faces Securities Class Action Lawsuit
Aardvark Therapeutics is facing multiple securities class action lawsuits alleging that the company made false and misleading statements during its February 2025 IPO regarding the safety and efficacy of its lead drug candidate, ARD-101. These lawsuits follow a voluntary pause and subsequent full clinical …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
Pomerantz LLP has filed a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and its officers and directors. The lawsuit alleges that Aardvark made false and misleading statements regarding its lead product candidate, ARD-101, which resulted in significant stock price drops after the …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Is Deutsche Telekom (DTEGY) Outperforming Other Utilities Stocks This Year?
For those looking to find strong Utilities stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Deutsche Telekom AG (DTEGY) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison …
Sharemaestro market context Price below Trend Line 52 weeks -5.8% · Next-week setup positive 57.5%Is The Chef's Warehouse (CHEF) Stock Outpacing Its Consumer Staples Peers This Year?
The Consumer Staples group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Chefs' Warehouse (CHEF) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to …
CHEF
main company
Sharemaestro market context
Trend signal active
52 weeks +70.2% · Next-week setup positive 56.7%
Tenet (THC) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before …
THC
main company
Sharemaestro market context
Trend signal active
52 weeks +49.2% · Next-week setup positive 56.2%
Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations
Travere Therapeutics (TVTX) saw its stock rise by 6.1% following news that its drug FILSPARI's launch for FSGS is exceeding expectations, driven by strong physician demand. This success reinforces the company's kidney-focused portfolio, which also includes a Phase III trial for pegtibatinase and the …
TVTX
main company
Sharemaestro market context
Trend signal active
52 weeks +246.8% · Next-week setup positive 56.5%
RLAY Maintained by HC Wainwright & Co. -- Price Target Raised to $29
HC Wainwright & Co. has maintained a "Buy" rating for Relay Therapeutics (RLAY) and raised its price target to $29, reflecting cautious optimism despite the company's financial challenges. However, GuruFocus's GF Value™ indicates RLAY is significantly overvalued by 493.4%, and its GF Score™ of …
RLAY
main company
Sharemaestro market context
Trend signal active
52 weeks +438.2% · Next-week setup positive 59.6%
Smucker's incoming science chief brings more than 25 years in food leadership
The J.M. Smucker Co. (NYSE:SJM) has elected Jeff Varcoe, PhD, as Senior Vice President, Science and Technical Excellence, effective August 24, 2026. Varcoe will lead operational excellence across all technical disciplines, including product quality, compliance, and innovation, reporting to Rob Ferguson, Chief Product Supply …
SJM
main company
Sharemaestro market context
Trend signal active
52 weeks +10.6% · Next-week setup negative 42.1%